HomeAboutRankingsData Sources
© 2026 GeneE
🧬
GeneE
10 sources retrieved · Most recent: April 2026 · Index updated 14 days ago
ⓘGeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
MAFG
MAF bZIP transcription factor G
Chromosome 17 · 17q25.3
NCBI Gene: 4097Ensembl: ENSG00000197063.12HGNC: HGNC:6781UniProt: O15525
77PubMed Papers
20Diseases
0Drugs
0Pathogenic Variants
FUNCTIONAL ROLE
Transcription Factor
DATA QUALITY
✓ Experimental GO Evidence✓ Swiss-Prot Reviewed
protein bindingidentical protein bindingsequence-specific double-stranded DNA bindingregulation of epidermal cell differentiationhereditary breast ovarian cancer syndromeHereditary breast and ovarian cancer syndromebreast cancerhepatocellular carcinoma
✦AI Summary

MAFG (MAF bZIP transcription factor G) is a small basic-zipper transcription factor that functions primarily as a transcriptional repressor when forming homodimers, but acts as a transcriptional activator when heterodimerizing with larger bZIP proteins like NFE2L2 1. MAFG regulates antioxidant and anti-inflammatory gene expression by interacting with NRF2/NFE2L2 at specific DNA-binding sites and recruiting coactivators such as MYH9 23. Mechanistically, MAFG controls ferroptosis—iron-dependent programmed cell death—by transcriptionally activating ferroptosis-suppressor genes including lipocalin 2 (LCN2), heme oxygenase-1, and quinone oxidoreductase-1 234. MAFG also cooperates with MAT2α to promote DNA methylation and repress antioxidant programs 5. Clinically, MAFG dysregulation is implicated in multiple pathological conditions. Elevated MAFG expression in astrocytes drives CNS inflammation in experimental autoimmune encephalomyelitis and multiple sclerosis 5. In hepatocellular carcinoma and liver fibrosis, MAFG suppresses ferroptosis in stellate cells, promoting fibrosis progression; therapeutic targeting via ferroptosis induction shows promise 3. MAFG also mediates immune suppression and stemness reprogramming in HCC 6, and its stabilization contributes to placental inflammation in placenta accreta spectrum 7. NRF2-MAFG complex disruption enhances chemotherapy sensitivity in KEAP1-deficient lung cancers 8.

Sources cited
1
MAFG functions as transcriptional repressor in homodimers and activator in heterodimers with NFE2L2 and other bZIP proteins
PMID: 11154691
2
MAFG is increased in EAE/MS astrocytes and cooperates with MAT2α to promote DNA methylation and repress antioxidant/anti-inflammatory programs, driving CNS inflammation
PMID: 32051591
3
MAFG heterodimerizes with NRF2 to activate ferroptosis-suppressive genes including quinone oxidoreductase-1, heme oxygenase-1, and ferritin heavy chain-1 in HCC
PMID: 26403645
4
MAFG interacts with MYH9 to transcriptionally activate LCN2 expression, suppressing ferroptosis in hepatic stellate cells and promoting liver fibrosis
PMID: 38871948
5
FXR-activated MAFG acts as transcriptional repressor binding ferroptosis-related genes Hmox1, Nqo1, and Tf in cisplatin-induced AKI
PMID: 35767918
6
MAFG-NRF2 protein complex binding to regulatory DNA sequences can be disrupted by ML385 to enhance chemotherapy sensitivity in KEAP1-deficient NSCLC
PMID: 27552339
7
MAFG is identified as a senescence-related gene potentially mediating immune suppression, senescence, and stemness in HCC
PMID: 38614215
8
MAFG stabilization through Piezo1-PKC signaling drives NF-κB-dependent stromal inflammation in placenta accreta spectrum
PMID: 39333481
Disease Associationsⓘ20
Hereditary breast and ovarian cancer syndromeOpen Targets
0.12Weak
hereditary breast ovarian cancer syndromeOpen Targets
0.12Weak
breast cancerOpen Targets
0.11Weak
hepatocellular carcinomaOpen Targets
0.10Suggestive
melanomaOpen Targets
0.10Suggestive
esophageal squamous cell carcinomaOpen Targets
0.09Suggestive
posterior cortical atrophyOpen Targets
0.09Suggestive
colorectal carcinomaOpen Targets
0.08Suggestive
neoplasmOpen Targets
0.08Suggestive
SepsisOpen Targets
0.08Suggestive
prostate cancerOpen Targets
0.08Suggestive
urinary bladder carcinomaOpen Targets
0.08Suggestive
glioblastoma multiformeOpen Targets
0.08Suggestive
osteosarcomaOpen Targets
0.07Suggestive
pachyonychia congenitaOpen Targets
0.07Suggestive
non-small cell lung carcinomaOpen Targets
0.05Suggestive
thrombocytopenia 7Open Targets
0.04Suggestive
cancerOpen Targets
0.04Suggestive
ThrombocytopeniaOpen Targets
0.04Suggestive
bladder transitional cell carcinomaOpen Targets
0.04Suggestive
Pathogenic Variants
No pathogenic variants reported on ClinVar for this gene.
View on ClinVar ↗
Related Genes
NFE2Protein interaction99%BACH2Protein interaction98%BACH1Protein interaction98%MAFKProtein interaction97%NFE2L1Protein interaction96%NFE2L3Protein interaction94%
Tissue Expression6 tissues
Bone Marrow
100%
Lung
73%
Ovary
40%
Heart
39%
Brain
38%
Liver
29%
Gene Interaction Network
Click a node to explore
MAFGNFE2BACH2BACH1MAFKNFE2L1NFE2L3
PROTEIN STRUCTURE
Preparing viewer…
PDB7X5E · 2.30 Å · X-ray
View on RCSB ↗
Constraintⓘ
LOEUFⓘ
0.81LoF Tolerant
pLIⓘ
0.59Intermediate
Observed/Expected LoF0.31 [0.14–0.81]
RankingsWhere MAFG stands among ~20K protein-coding genes
  • #6,178of 20,598
    Most Researched77
  • #6,754of 17,882
    Most Constrained (LOEUF)0.81
Genes detectedMAFG
Sources retrieved10 papers
Response time—
📄 Sources
10▼
1
MAFG-driven astrocytes promote CNS inflammation.
PMID: 32051591
Nature · 2020
1.00
2
Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells.
PMID: 26403645
Hepatology · 2016
0.90
3
MafG/MYH9-LCN2 axis promotes liver fibrosis through inhibiting ferroptosis of hepatic stellate cells.
PMID: 38871948
Cell Death Differ · 2024
0.80
4
Cross-disorder and disease-specific pathways in dementia revealed by single-cell genomics.
PMID: 39265576
Cell · 2024
0.70
5
Farnesoid X receptor protects against cisplatin-induced acute kidney injury by regulating the transcription of ferroptosis-related genes.
PMID: 35767918
Redox Biol · 2022
0.60